Tvardi Therapeutics Inc

Tvardi Therapeutics operates with a high liquidity position, as evidenced by $49.24 million in cash and equivalents, which significantly exceeds its total liabilities of $60.90 million, resulting in a current ratio of 4.59. The company's price-to-book ratio of 3.2 and price-to-tangible-book ratio of 3.2 suggest that the market is valuing the company at a premium to its book value, despite its negative net income of $20.02 million. The company's profitability metrics are weak, with a return on equity of -1.73 and a return on assets of -0.28, both significantly below the industry median for biotechnology firms. The operating loss of $18.80 million and net loss of $20.02 million indicate that the company is not yet generating positive returns for shareholders. Tvardi Therapeutics does not disclose segment or geographic revenue breakdowns in the available data, so it is not possible to assess revenue concentration or geographic exposure at this time. The company's growth trajectory is uncertain, as the available data does not include forward-looking revenue guidance or historical growth rates. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 3.42 indicates a relatively high level of leverage, but the company's cash position provides a buffer against short-term liquidity pressures. No dilution risks were identified in the available data, and the number of shares outstanding has not changed between basic and diluted shares. Recent events include analyst price targets ranging from $3.00 to $15.00, with a mean of $8.17 and a median of $8.00. Analysts have issued a total of 2 strong-buy, 2 buy, and 3 hold recommendations, indicating a generally positive but cautious outlook.